Clinical Trial Update: Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of WC3055 in men with lower urinary tract symptoms due to benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• WC3055

Snippet

Sponsor: Warner Chilcott | Conditions: Benign Prostatic Hyperplasia | Phase 2 | Status: COMPLETED